Rebound hyperammonemia triggered by interruption of renal replacement therapy in adolescent ornithine transcarbamylase deficiency
The Journal of Medical Investigation · 2025
DOI: 10.2152/jmi.72.443 ↗Kurz gefasst
Fallbericht in der Zeitschrift The Journal of Medical Investigation, 2025. Verfasst von Yuki Nakano und 13 weiteren Autor:innen. Beteiligte Einrichtung: Emergency Department, Tokushima Prefectural Miyoshi Hospital, Tokushima, Japan. Hauptthemen laut MEDLINE: Ornithine Carbamoyltransferase Deficiency Disease, Hyperammonemia, Renal Replacement Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Ornithine transcarbamylase (OTC) deficiency is the most common urea cycle disorder (UCD) and may lead to life-threatening hyperammonemia. Refractory cases require prompt and aggressive treatment, including renal replacement therapy (RRT), to prevent irreversible neurological damage. CASE PRESENTATION: We encountered a 14-year-old girl with OTC deficiency who presented with severe hyperammonemia (649 µg/dL;382 µmol/L). Pharmacological therapy and emergency intermittent hemodialysis (IHD) were followed by continuous hemodiafiltration (CHDF), resulting in rapid ammonia clearance. However, a 4-h interruption of CHDF due to catheter replacement led to rebound hyperammonemia (>500 µg/dL;>294 µmol/L), requiring resumption of RRT on day 4. OTC deficiency was subsequently diagnosed based on plasma amino acid and urine organic acid analyses on day 12. After intensifying the pharmacological therapy and achieving stable ammonia levels, RRT was discontinued on day 17. The patient recovered without apparent neurological sequelae and was discharged from the intensive-care unit. CONCLUSIONS: This case highlights the importance of uninterrupted RRT in managing acute hyperammonemia and suggests that even short pauses in CHDF can provoke clinically significant rebound. Early initiation of RRT, continuous monitoring of ammonia levels, and individualized treatment strategies are critical for optimizing patient outcomes. J. Med. Invest. 72 : 443-446, August, 2025.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Emergency Department, Tokushima Prefectural Miyoshi Hospital, Tokushima, Japan.
- Emergency and Critical Care Medicine, Tokushima University Hospital, Tokushima, Japan.
- Emergency Department, Tokushima Prefectural Kaifu Hospital, Tokushima, Japan.
- Department of Emergency and Disaster Medicine, Tokushima University Hospital, Tokushima, Japan.
- Department of Emergency and Critical Care Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima University Hospital, Tokushima, Japan.
Zitieren
APA
Nakano, Y., Otani, S., Terazawa, M., Moriwaki, K., Saijo, S., Bando, N., Momota, K., Sato, H., Takashima, T., Nunomura, T., Ishihara, M., Ueno, Y., Itagaki, T., & Oto, J. (2025). Rebound hyperammonemia triggered by interruption of renal replacement therapy in adolescent ornithine transcarbamylase deficiency. The Journal of Medical Investigation. https://doi.org/10.2152/jmi.72.443
Vancouver
Nakano Y, Otani S, Terazawa M, Moriwaki K, Saijo S, Bando N, et al. Rebound hyperammonemia triggered by interruption of renal replacement therapy in adolescent ornithine transcarbamylase deficiency. The Journal of Medical Investigation. 2025. doi:10.2152/jmi.72.443
BibTeX
@article{Nakano2025,
author = {Nakano, Yuki and Otani, Shotaro and Terazawa, Masaki and Moriwaki, Konomi and Saijo, Saki and Bando, Natsuki and Momota, Kazuki and Sato, Hiroki and Takashima, Takuya and Nunomura, Toshiyuki and Ishihara, Manabu and Ueno, Yoshitoyo and Itagaki, Taiga and Oto, Jun},
title = {Rebound hyperammonemia triggered by interruption of renal replacement therapy in adolescent ornithine transcarbamylase deficiency},
journal = {The Journal of Medical Investigation},
year = {2025},
doi = {10.2152/jmi.72.443}
}
EUVIMED